Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› District of Columbia
Clinical trial register · United States · industry-sponsored

Clinical Trials in District of Columbia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca45 Merck Sharp & Dohme LLC44 Pfizer25 Novartis Pharmaceuticals24 Hoffmann-La Roche22
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in District of Columbia

802 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420Advanced Breast Cancer, Early Breast Cancer
DrugZoladex
TerSera Therapeutics LLC
Phase 1
176
Arkansas, District of Columbia, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2026-10-30
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
District of Columbia, Florida, Illinois, Kentucky
2026-10-19
Not yet open
Knee Cartilage Repair Registry
NCT07786207Knee Injuries, Joint Surface Knee Lesions
Smith & Nephew, Inc.
Observational
1,000
Colorado, District of Columbia, Indiana, Kentucky, Oklahoma, Pennsylvania
2026-09-30
Recruiting
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
NCT07799532Chronic Spinal Cord Injury
NervGen Pharma
Phase 3
150
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Maryland
2026-09-28
Recruiting
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
NCT07668414Overweight, Obesity
DrugsZenagamtide·Semaglutide
Novo Nordisk A/S
Phase 3
650
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri
2026-09-22
Recruiting
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
NCT07776691Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
DrugsR-DXd·Mvasi·Avastin·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
802
District of Columbia, Texas
2026-09-18
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
DrugElritercept
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Montana
2026-09-10
Recruiting
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
NCT07815665Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
DrugsEnfortumab Vedotin·Pembrolizumab
Summit Therapeutics
Phase 2/3
800
Arizona, California, District of Columbia, Florida, Minnesota, Tennessee, Washington
2026-09-10
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200Essential Thrombocythemia
DrugINCA033989
Incyte Corporation
Phase 3
426
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-09-08
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2026-09-01
Recruiting
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
NCT07768345Respiratory Syncytial Virus (RSV)
DrugRSVpreF Vaccine
Pfizer
Phase 3
440
California, District of Columbia, Georgia, New York, North Carolina, Pennsylvania
2026-08-31
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463Obesity, Overweight, Chronic Weight Management
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-31
Not yet open
Safety Study of Microlyte DualGuard
NCT07695688Wound Closure, Wound Care
Imbed Biosciences
Not applicable
53
Arizona, District of Columbia, Louisiana
2026-08-30
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-28
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)
DrugDanicamtiv
Kardigan, Inc.
Phase 3
332
Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts
2026-08-26
Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
DrugApraglutide
VectivBio AG
Phase 3
124
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Michigan, New York
2026-08
Not yet open
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
NCT06458907Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
P+F Products + Features USA Inc.
Not applicable
780
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2026-08
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Louisiana
2026-07-27
Recruiting
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
NCT07734649Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
DrugHMPV vaccine
Sanofi
Phase 1/2
2,400
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-07-22
Recruiting
Study of GS-0415 and How It Works in People With HIV
NCT07719491HIV -1 Infection
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NCT07324031Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
AtaCor Medical, Inc.
Not applicable
280
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kentucky
2026-07-02
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Alabama, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2026-07-01
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916HIV Infections
DrugsCab Ula·Rpv La·Cabotegravir
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Maryland, Michigan
2026-06-25
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597Stomatitis
DrugDato-DXd
AstraZeneca
Phase 4
100
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-06-24
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, North Carolina, Ohio, West Virginia
2026-06-23
Recruiting
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)
NCT07062471Carotid Artery Calcification, Carotid Artery Diseases
Shockwave Medical, Inc.
Not applicable
185
Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Minnesota
2026-06-22
Recruiting
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032Relapsed/Refractory Primary Central Nervous System Lymphoma
DrugsTirabrutinib·Temozolomide·Rituximab
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, Minnesota
2026-06-12
Recruiting
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
NCT07258290Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis
Teleflex
Not applicable
1,859
District of Columbia, West Virginia
2026-06-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Not yet open
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
NCT07676097Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
AngioInsight
Observational
620
California, District of Columbia, Minnesota, New Jersey, New York, Ohio, Tennessee
2026-06
Recruiting
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
NCT06915233Chondral Defect, Articular Cartilage Defect
Vericel Corporation
Phase 3
309
California, District of Columbia, Kansas, North Carolina, Texas, Virginia
2026-05-28
Recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 2
60
California, District of Columbia, Florida, Georgia, New York, North Carolina, Pennsylvania, Washington
2026-05-20
Recruiting
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
NCT06948214Growth Hormone Deficiency (GHD)
DrugLUM-201
Lumos Pharma
Phase 3
150
Alabama, California, Colorado, District of Columbia, Florida, Indiana, Iowa, Louisiana
2026-05-20
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 3
350
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-05-14
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
DrugsTemodar·Temozolomide
Black Diamond Therapeutics, Inc.
Phase 2
162
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Maryland
2026-05-05
Recruiting
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
NCT07335588Lichen Sclerosus
DrugDelgocitinib
LEO Pharma
Phase 3
652
Alabama, Arizona, California, District of Columbia, Florida, Minnesota, New York, Ohio
2026-05-01
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina, Ohio
2026-04-23
Recruiting
Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study
NCT07579312Intra Abdominal Infections, Appendicitis Acute, Pyelonephritis, Diverticulitis
True Bearing Diagnostics, Inc.
Observational
1,000
District of Columbia
2026-04-17
Recruiting
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
NCT07210515Complex Regional Pain Syndrome Type I
Ambros Therapeutics, Inc.
Phase 3
270
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-04-14
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Not yet open
Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool
NCT05311046Sepsis
Computer Technology Associates, Inc.
Observational
12,961
District of Columbia
2026-04-01
Not yet open
Analysis of ECGio to Predict Coronary Stenosis Against a Mixed Reference Standard
NCT07375810Coronary Artery Disease (CAD)
Heart Input Output Inc
Observational
978
District of Columbia, Texas
2026-04-01
Recruiting
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
DrugsTam-Peli·Atezolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
District of Columbia, Florida, Kentucky, Texas, Virginia
2026-03-31
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy
Bristol-Myers Squibb
Phase 1/2
474
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Maryland, Michigan
2026-03-26
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 3
770
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-24
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Louisiana
2026-03-23
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
DrugsPF-08634404·Enfortumab Vedotin
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
DrugsINCA33890·Folfox·Bevacizumab
Incyte Corporation
Phase 3
700
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-05
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
DrugIDE397
IDEAYA Biosciences
Phase 1
260
Arizona, California, District of Columbia, Florida, Illinois, Minnesota, Nebraska, New Jersey
2026-03-04
Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
NCT07166133Aortic Arch Dissection, Aortic Arch Aneurysm
W.L.Gore & Associates
Not applicable
125
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, North Carolina, Pennsylvania
2026-03-02
Recruiting
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
NCT07335341Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity
Medtronic Endovascular
Observational
50
District of Columbia, Florida, New York, Texas
2026-02-24
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
DrugsAZD0120·Darzalex·Velcade·Carfilzomib
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
A Study to Learn About mRNA Vaccines Against Influenza in Adults
NCT07431853Healthy Adults
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Active, closed
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07435428Moderate to Severe Glabellar Lines
DrugCorabotase
Ipsen
Phase 3
1,300
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-18
Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497Locally Advanced / Metastatic Solid Tumors
Crescent Biopharma, Inc.
Phase 1/2
290
Alabama, California, Colorado, District of Columbia, Florida, Michigan, New York, Ohio
2026-02-17
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-02-16
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723Symptomatic Genetic Dilated Cardiomyopathy
DrugDanicamtiv
Kardigan, Inc.
Phase 2/3
332
Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts
2026-02-13
Recruiting
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
NCT07080385Autosomal Dominant Hypocalcemia Type 1 (ADH1)
DrugEncaleret
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 2/3
28
Connecticut, District of Columbia, Florida, Pennsylvania
2026-01-30
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177Non-small Cell Lung Cancer (NSCLC)
DrugRina-S
Genmab
Phase 2
240
California, District of Columbia, Florida, Georgia, Montana, Nebraska, New Jersey, New York
2026-01-30
Recruiting
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
NCT07428538Hepatitis
Bausch Health Americas, Inc.
Phase 3
350
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-01-29
By invitation
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT07286006Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
California, District of Columbia, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2026-01-16
Recruiting
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
DrugDescartes-08
Cartesian Therapeutics
Phase 1/2
50
District of Columbia, Missouri, Ohio
2026-01-14
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
DrugsRondecabtagene autoleucel·Axi-cel·Breyanzi·Lisocabtagene maraleucel
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454Depressive Disorder, Major
DrugsEsketamine·Midazolam
Janssen Research & Development, LLC
Phase 3
258
Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio
2026-01-08
By invitation
Lead Evaluation for Defibrillation and Reliability Post Approval Study
NCT07005232Tachyarrhythmia
Medtronic
Observational
2,000
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2026-01-07
Recruiting
The ArtixASCEND Study
NCT07135895Acute Lower Limb Arterial Occlusion
Inari Medical
Not applicable
250
California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2026-01-07
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
California, Colorado, District of Columbia, Florida, Iowa, Massachusetts, New Jersey, New York
2026-01-05
Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 2
120
California, Colorado, District of Columbia, Illinois, Minnesota, Nebraska, New York, Tennessee
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-12-29
Recruiting
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
NCT07254806Degenerative Disc Disease
DiscGenics, Inc.
Phase 3
162
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Indiana, Kentucky
2025-12-23
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-12-22
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugB/F/TAF
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Ascendis Pharma A/S
Phase 3
186
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho, Louisiana
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Breast Cancer, Metastatic
DrugsEvorpacept·Eribulin·Herceptin·Vinorelbine
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Active, closed
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839COVID-19, SARS-COV-2 Infection
DrugBNT162b2 Vaccine
BioNTech SE
Phase 3
5,240
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-10
Recruiting
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
NCT07282665Clostridoides Difficile Associated Disease
Pfizer
Phase 3
32,500
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-12-10
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin
2025-12-09
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa
2025-12-03
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
DrugBelumosudil
Sanofi
Phase 2
37
California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington
2025-12-02
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Active, closed
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558SARS-CoV-2
DrugsMRNA-1283·Efluelda (TIV-HD) and Spikevax
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
Recruiting
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
NCT07209397Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
InMode MD Ltd.
Not applicable
202
California, District of Columbia, Idaho, Illinois, Kansas, Massachusetts, Nebraska, Nevada
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419Diabetic Peripheral Neuropathic Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 3
734
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-11-21
Recruiting
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
NCT07226258Osteoarthritis Knee Pain
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-11-04
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDato-DXd·Docetaxel
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06701656Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugBevacizumab
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-10-28
Recruiting
A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
NCT07127978Duchene Muscular Dystrophy
ITF Therapeutics LLC
Observational
300
Arkansas, District of Columbia, Illinois, Massachusetts, New York, North Carolina, Oregon, Washington
2025-10-23
Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738Heart Failure - NYHA II - IV
Boston Scientific Corporation
Not applicable
850
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-10-22
Recruiting
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811Ig-E Mediated Food Allergy
DrugOzureprubart
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
100
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts
2025-10-22
Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT07023614Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Phase 2
165
California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-10-06
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Hawaii
2025-10-03
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2025-10-02
Recruiting
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Maryland, Massachusetts
2025-09-30
Recruiting
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
NCT07095127Immune Thrombocytopenia (ITP)
DrugNVG-2089
Nuvig Therapeutics, Inc.
Phase 2
30
District of Columbia, Massachusetts, North Carolina
2025-09-30
Active, closed
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
NCT07159763Influenza
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-09-25
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
DrugsBNT326·Pumitamig
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-09-22
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Alabama, California, Colorado, District of Columbia, Florida, Louisiana, Pennsylvania, Tennessee
2025-09-16
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-09-08
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Iowa
2025-09-04
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz North America, Inc.
Phase 3
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-08-27
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
DrugsCapivasertib·Fulvestrant
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Alabama, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland
2025-08-22
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
DrugTaletrectinib
Nuvation Bio Inc.
Phase 3
180
California, District of Columbia, Florida, Idaho, Louisiana, Massachusetts, Minnesota, New York
2025-08-21
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Active, closed
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872Type 2 Diabetes Mellitus
DrugsRO7795081·Semaglutide
Hoffmann-La Roche
Phase 2
330
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, New York
2025-08-19
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
DrugRilzabrutinib
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, Minnesota
2025-08-18
Recruiting
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103Solid Tumors
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07029581Lewy Body Dementia Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 2
180
California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Kansas, New York
2025-08-06
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
UroGen Pharma Ltd.
Phase 3
70
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Iowa, Nebraska
2025-08-06
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Arizona, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2025-08-05
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maine
2025-08-01
Recruiting
OM336 in Autoimmune Cytopenias
NCT07083960AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Lakefront Biotherapeutics West LLC
Phase 1
32
California, District of Columbia, Michigan, Washington
2025-08-01
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Active, closed
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
NCT07044297Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
DrugMK-8527
Merck Sharp & Dohme LLC
Phase 3
4,390
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Mississippi
2025-07-31
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Arizona, California, District of Columbia, Illinois, Maryland, Minnesota, Missouri, Texas
2025-07-30
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
DrugPirtobrutinib
Eli Lilly and Company
Phase 1/2
68
California, District of Columbia, Florida, Illinois, Louisiana, Minnesota, Texas
2025-07-30
Recruiting
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
NCT06422871End Stage Renal Disease, Hemodialysis Access Failure
Merit Medical Systems, Inc.
Observational
100
District of Columbia, Florida, North Carolina, Pennsylvania, Texas, Virginia
2025-07-28
Not yet open
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
NCT06989567Sickle Cell Disease
DrugL-Citrulline
Asklepion Pharmaceuticals, LLC
Phase 3
120
District of Columbia, Florida, Georgia, Maryland, Michigan, North Carolina
2025-07-25
Recruiting
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Arizona, California, Colorado, District of Columbia, Georgia, Illinois, Indiana, Kansas
2025-07-25
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine, Massachusetts
2025-07-23
Active, closed
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
NCT07047716HIV Pre-exposure Prophylaxis
DrugLenacapavir
Gilead Sciences
Phase 3
339
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Louisiana
2025-07-22
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Alabama, Arizona, California, District of Columbia, Florida, Kentucky, Louisiana, Massachusetts
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
NCT06950385Familial Adenomatous Polyposis (FAP)
DrugERapa
Rapamycin Holdings Inc.
Phase 3
168
California, Connecticut, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-07-18
Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712Gastroesophageal Adenocarcinoma
DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan
AstraZeneca
Phase 2
100
Delaware, District of Columbia, Kansas, Michigan, New York, Pennsylvania
2025-07-17
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Veklury·Remdesivir
Pfizer
Phase 3
300
California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2025-07-14
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Recruiting
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
NCT06868212Chronic Spontaneous Urticaria (CSU)
DrugsRemibrutinib·Dupilumab
Novartis Pharmaceuticals
Phase 3
400
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-07-11
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide
Merck Sharp & Dohme LLC
Phase 1/2
360
California, District of Columbia, Michigan, New York, Pennsylvania, Tennessee, Washington
2025-07-03
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-02
Active, closed
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453Breast Cancer, Breast Neoplasms
DrugDisitamab Vedotin
Pfizer
Phase 1/2
74
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-30
By invitation
Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy
NCT07046832Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma
MediView XR, Inc.
Not applicable
104
District of Columbia, New York
2025-06-27
Active, closed
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919Allergy, Peanut Allergy
DBV Technologies
Phase 3
480
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-06-24
Active, closed
VK2735 for Weight Management Phase 3
NCT07104500Weight Loss
DrugVK2735
Viking Therapeutics, Inc.
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-06-23
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT06701682Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugVilobelimab
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-21
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Minnesota, Missouri
2025-06-20
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Arizona, California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts
2025-06-19
Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NCT06608823Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
JenaValve Technology, Inc.
Not applicable
1,016
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-06-18
Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
NCT06944522Parkinsons Disease (PD)
BlueRock Therapeutics
Phase 3
102
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas
2025-06-17
Active, closed
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
NCT06699836Metastatic Colorectal Cancer (mCRC)
DrugsLeronlimab·Keytruda·Pembrolizumab
CytoDyn, Inc.
Phase 2
66
California, District of Columbia, Kentucky, Nebraska, Pennsylvania, Washington
2025-06-16
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
NCT06701669Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugParidiprubart
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
DrugsDoxorubicin·Docetaxel·Paclitaxel
BioNTech SE
Phase 3
480
Connecticut, District of Columbia, Florida, Illinois, Louisiana, Nevada, New York, Ohio
2025-06-10
Active, closed
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
NCT06914609Angelman Syndrome
DrugObudanersen
Ionis Pharmaceuticals, Inc.
Phase 3
156
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Missouri
2025-06-10
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT06703073Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugsParidiprubart·Vilobelimab·Bevacizumab
PPD Development, LP
Phase 2
600
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-09
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984Agitation, Alzheimer Disease
DrugIrafamdastat
Celgene
Phase 2
120
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-06-09
Active, closed
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984Chikungunya Virus
Bavarian Nordic
Phase 3
720
California, District of Columbia, Florida, Nebraska, Ohio, Texas, Utah
2025-06-05
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
DrugZorevunersen
Stoke Therapeutics, Inc
Phase 3
170
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Massachusetts
2025-06-04
Recruiting
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
NCT07038343Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
Avenzo Therapeutics, Inc.
Phase 1/2
480
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts
2025-06-04
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
Arizona, California, District of Columbia, Florida, Massachusetts, New Jersey, New York, Ohio
2025-06-01
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
DrugsTNG462·RMC-9805·Gemcitabine-nab-paclitaxel·MFOLFIRINOX
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Recruiting
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916Generalized Myasthenia Gravis
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 3
231
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-05-27
Recruiting
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
NCT06941025Fabry Disease, Pregnancy, Pregnancy Complications
Chiesi Farmaceutici S.p.A.
Observational
10
District of Columbia
2025-05-23
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Iowa
2025-05-22
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,123
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-22
Recruiting
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
NCT06834165Allergic Reactions
DrugAdrenaline
ARS Pharmaceuticals, Inc.
Phase 4
600
California, District of Columbia, Illinois, Michigan, New York, Ohio
2025-05-20
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Recruiting
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729Acute Treatment of Migraine
Pfizer
Phase 1
16
District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Ohio, Oklahoma
2025-05-16
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maryland, Michigan
2025-05-15
Recruiting
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT06822426Central Line Associated Blood Stream Infections (CLABSI)
Drugs(taurolidine and heparin) catheter lock·Heparin
CorMedix Therapeutics
Phase 3
200
California, District of Columbia, Florida, Georgia, Illinois, Iowa, Maryland, Minnesota
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-13
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-05-12
Active, closed
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247Myasthaenia Gravis
Cartesian Therapeutics
Phase 3
128
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2025-05-06
Recruiting
Motiva Implants® Post-Approval Study
NCT06938399Breast Implant
Motiva USA LLC
Not applicable
2,400
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Louisiana, Maryland
2025-05-01
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970Sickle Cell Disease
DrugTebapivat
Agios Pharmaceuticals, Inc.
Phase 2
59
Connecticut, District of Columbia, Georgia, Michigan, New York, Pennsylvania, South Carolina, Texas
2025-05-01
Recruiting
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085Lymphoma
DrugsGlofitamab·Tocilizumab·Obinutuzumab·Oxaliplatin
Hoffmann-La Roche
Phase 1
50
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maryland, New Mexico
2025-04-28
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Active, closed
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
NCT06891066Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugB/F/TAF
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 2
594
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-04-11
Active, closed
ASCEND CSP IDE Study
NCT06830746Heart Failure, Ventricular Arrythmia
Abbott Medical Devices
Not applicable
414
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Massachusetts, New York
2025-04-11
Active, closed
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264HEPATITIS C VIRUS CHRONIC INFECTION
DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-04-07
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165ALS
Amylyx Pharmaceuticals Inc.
Phase 1
48
California, District of Columbia, Florida, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2025-04-07
Active, closed
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 3
43
California, District of Columbia, Florida, Kentucky, Michigan, North Carolina, Ohio, Texas
2025-04-07
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Recruiting
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
NCT06664775Hemorrhage
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Active, closed
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
NCT06864169Gastrointestinal Cancer
DrugR-DXd
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Active, closed
TECTONIC CAD IVL IDE Study
NCT06885177Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Abbott Medical Devices
Not applicable
335
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2025-04-01
Active, closed
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812Solid Tumors
DrugsGEMNabP·MFOLFIRINOX·Cetuximab
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Boston Scientific Corporation
Observational
1,500
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Illinois
2025-03-26
Recruiting
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785Advanced Solid Tumor
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
DrugAbemaciclib
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2025-03-18
Recruiting
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571Plasma Cell Myeloma Refractory
DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab
Sanofi
Phase 2
64
Arizona, California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho
2025-03-16
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-03-13
Active, closed
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Alabama, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2025-03-12
Recruiting
Non-invasive Central Venous Pressure Estimation in Pediatric Patients
NCT06885073Central Venous Pressure
Compremium AG
Not applicable
100
District of Columbia
2025-03-10
Active, closed
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
DrugALN-4324
Alnylam Pharmaceuticals
Phase 1/2
105
California, District of Columbia, Florida, New Jersey, North Carolina, Texas
2025-03-03
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
9
California, District of Columbia, Missouri, Utah
2025-02-28
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
Identifying Patterns in the Breath of Individuals With Breast Cancer
NCT06512350Breast Cancer
Breathe BioMedical Inc
Observational
5,175
District of Columbia, Florida, North Carolina, Pennsylvania
2025-02-25
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-02-24
Active, closed
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194Pneumococcal Immunization
DrugsHavrix·Vaqta·M-M-R II vaccine·Prevnar 20 vaccine
Sanofi
Phase 3
2,360
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-02-18
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
DrugEtavopivat
Novo Nordisk A/S
Phase 3
510
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-02-17
Recruiting
Apple Health Study
NCT06958523Mental Health, Sleep, Exercise, Hormones
Apple Inc.
Observational
500,000
District of Columbia, Massachusetts
2025-02-12
Recruiting
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
NCT06541847Neurofibromatosis Type 1
Healx Limited
Phase 2
25
Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri
2025-02-10
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
DrugClaseprubart
Dianthus Therapeutics
Phase 3
256
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Hawaii, Illinois
2025-02-10
Active, closed
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Recruiting
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368Aortic Stenosis
Medtronic Cardiovascular
Observational
225
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana
2025-02-06
Recruiting
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629Proteinuric Kidney Disease
Maze Therapeutics
Phase 2
74
Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2025-02-05
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
DrugsTemozolomide·Keytruda·Pembrolizumab
NovoCure GmbH
Phase 3
741
Arizona, California, District of Columbia, Florida, Illinois, Kentucky, Maryland, Massachusetts
2025-02-03
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
DrugOlutasidenib
Rigel Pharmaceuticals
Phase 2
60
Colorado, District of Columbia, Florida, Illinois, Massachusetts, North Carolina, Ohio, Pennsylvania
2025-02-01
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
United Therapeutics
Observational
900
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-23
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone
Incyte Corporation
Phase 3
240
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-21
Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551Degenerative Disc Disease (DDD)
ReGelTec, Inc.
Not applicable
225
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kansas, Louisiana
2025-01-13
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-01-10
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122Type 2 Diabetes
DrugDulaglutide
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics
Phase 1/2
675
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan
2025-01-09
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsAtirmociclib·Abemaciclib·Ribociclib·Palbociclib
Pfizer
Phase 3
1,035
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Recruiting
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410Cutaneous Squamous Cell Carcinoma (CSCC)
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
369
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-01-02
Active, closed
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
35
Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky
2024-12-30
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-12-18
Active, closed
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443Diabetic Peripheral Neuropathic Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 3
455
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-18
Active, closed
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06736041Pneumococcal Immunization
DrugsM-M-R II vaccine·Prevnar 20 vaccine·RotaTeq·PCV21 vaccine
Sanofi Pasteur, a Sanofi Company
Phase 3
1,714
Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-12-18
Recruiting
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406Metastatic Uveal Melanoma
DrugsRP2·Yervoy·Ipilimumab·Opdivo
Replimune, Inc.
Phase 2/3
280
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Iowa
2024-12-17
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
240
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Maine
2024-12-16
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Abbott Medical Devices
Not applicable
850
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
NCT06747858Cystic Fibrosis, CFTR Gene Mutation
Arcturus Therapeutics, Inc.
Phase 2
33
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Missouri
2024-12-12
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
60
California, District of Columbia, Florida, New York, Utah, Virginia, West Virginia
2024-12-09
Active, closed
The JenaValve ALIGN-AR LVAD Registry
NCT06594705Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
JenaValve Technology, Inc.
Not applicable
50
California, District of Columbia, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2024-12-09
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-08
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Arizona, California, District of Columbia, Illinois, Indiana, Kansas, Maryland, Massachusetts
2024-12-03
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2024-12-03
Active, closed
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805HIV Infections
DrugsRpv La·B/F/TAF·Cabotegravir
ViiV Healthcare
Phase 3
326
Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2024-12-02
Recruiting
CoMind Early Feasibility Study
NCT06368648Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage
CoMind Technologies Limited
Observational
581
Arizona, California, Delaware, District of Columbia, Florida, Iowa, Kansas, Missouri
2024-11-27
Active, closed
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
NCT06668805Noonan Syndrome
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
30
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-11-22
Active, closed
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
NCT06532656HIV-1-infection
DrugLenacapavir
Gilead Sciences
Phase 2/3
75
District of Columbia, Florida, Georgia, Illinois
2024-11-20
Active, closed
INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE
NCT06700109Osteoarthritis (OA) of the Knee
DrugTriamcinolone acetate
Brixton Biosciences, Inc.
Not applicable
263
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2024-11-19
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-11-19
Recruiting
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378Chronic Granulomatous Disease (CGD)
Ensoma
Observational
60
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-11-18
Recruiting
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
NCT06607627Generalized Myasthenia Gravis, gMG
Alexion Pharmaceuticals, Inc.
Phase 3
12
District of Columbia, Virginia
2024-11-13
Active, closed
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
DrugHMPV vaccine
Sanofi Pasteur, a Sanofi Company
Phase 1/2
1,530
Arizona, California, Colorado, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-11-11
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
367
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2024-11-11
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
DrugsBudesonide/Formoterol·Lunsekimig
Sanofi
Phase 2
556
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-11-07
Active, closed
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694Gastrointestinal Cancer
DrugPatritumab deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
180
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Nevada, New York
2024-11-03
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Arizona, California, District of Columbia, Florida, Illinois, Iowa, Kansas, Kentucky
2024-10-29
Recruiting
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082Sickle Cell Disease
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 3
354
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2024-10-24
Recruiting
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)
NCT06671132Chronic Pain, Low Back Pain
Evon Medics LLC
Phase 2
220
District of Columbia, Maryland
2024-10-23
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117Solid Tumor, MET Alteration
Pierre Fabre Medicament
Phase 1/2
140
District of Columbia, Ohio, Tennessee
2024-10-22
Recruiting
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
NCT06382155Idiopathic Short Stature
DrugsHuman Growth Hormone·Vosoritide
BioMarin Pharmaceutical
Phase 2
100
California, District of Columbia, Florida, Georgia, Idaho, Iowa, Kentucky, Louisiana
2024-10-21
Active, closed
Esprit BTK Post-Approval Study
NCT06656364Chronic Limb-Threatening Ischemia
Abbott Medical Devices
Not applicable
200
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-10-21
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Arizona, California, Colorado, Connecticut, District of Columbia, Illinois, Iowa, Louisiana
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Cetuximab
Janssen Research & Development, LLC
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-18
Recruiting
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-10-17
Active, closed
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844Non-small Cell Lung Cancer
DrugsRilvegostomig·Dato-DXd·Vinorelbine·Etoposide
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
DrugsISL/LEN·B/F/TAF
Gilead Sciences
Phase 3
609
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-09
Active, closed
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055SARS-CoV2, COVID-19
DrugComirnaty
Vaxart
Phase 2
5,485
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-08
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
DrugsAntiretroviral Combinations·ISL/LEN
Gilead Sciences
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-08
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-10-04
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237Multiple System Atrophy
DrugEmrusolmin
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
350
California, District of Columbia, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2024-10-02
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer
DrugNadofaragene Firadenovec
Ferring Pharmaceuticals
Phase 3
454
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-10-01
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908Diabetic Peripheral Neuropathic Pain
DrugsSuzetrigine·Pregabalin
Vertex Pharmaceuticals Incorporated
Phase 3
1,100
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-10-01
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab
Ferring Pharmaceuticals
Phase 3
250
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-01
Active, closed
SIMPLAAFY Clinical Trial
NCT06521463Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation
Not applicable
1,857
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-01
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
96
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2024-09-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
DrugsPetosemtamab·Pembrolizumab
Merus B.V.
Phase 3
699
Alabama, California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-09-25
Active, closed
ADVENT Post Approval Study
NCT06431815Paroxysmal Atrial Fibrillation
Boston Scientific Corporation
Observational
228
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts
2024-09-25
Recruiting
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
NCT06564974Duchenne Muscular Dystrophy
DrugVamorolone
Catalyst Pharmaceuticals, Inc.
Observational
250
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2024-09-25
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Cetuximab·Irinotecan·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-09-11
Recruiting
RevCore for In Stent Thrombosis
NCT06394739In-stent Thrombosis
Inari Medical
Observational
100
Connecticut, District of Columbia, Idaho, Maryland, New York, North Carolina, Ohio, Pennsylvania
2024-09-09
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-04
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
California, District of Columbia, Florida, Illinois, North Carolina, Pennsylvania, Tennessee, Utah
2024-09-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Lymphoma, Follicular
DrugsEndoxan·Golcadomide·Pegylated liposomal doxorubicin·Bendamustine
Celgene
Phase 2
95
Alabama, Alaska, Arizona, California, District of Columbia, Florida, Kansas, Minnesota
2024-08-30
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
California, District of Columbia, Georgia, Indiana, Minnesota, New Jersey, New York, South Carolina
2024-08-29
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
California, District of Columbia, Florida, Missouri, New Jersey, New York, Ohio, Pennsylvania
2024-08-21
Active, closed
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
NCT06544733HIV-1-Infection
DrugB/F/TAF
Gilead Sciences
Phase 2/3
675
Alabama, California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey
2024-08-20
Recruiting
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
NCT06386874Ischemic Stroke
BrainQ Technologies Ltd.
Not applicable
122
California, District of Columbia, Florida, Georgia, Illinois, Kansas, New Jersey, New York
2024-08-20
Recruiting
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
NCT06041594Pulmonary Embolism
Innova Vascular, Inc.
Not applicable
107
Alabama, Arizona, California, District of Columbia, Florida, Illinois, New York, North Carolina
2024-08-19
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab
Jazz Pharmaceuticals
Phase 3
550
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Minnesota, Missouri
2024-08-13
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2024-08-12
Recruiting
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979Idiopathic Short Stature
BioMarin Pharmaceutical
Observational
300
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-08-08
Recruiting
Study of XB010 in Subjects With Solid Tumors
NCT06545331Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
DrugPembrolizumab
Exelixis
Phase 1
396
California, District of Columbia, Florida, Georgia, Illinois, Missouri, New York, North Carolina
2024-08-06
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 3
3,000
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-08-05
Active, closed
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
NCT06524414Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 2
605
Arkansas, California, District of Columbia, Florida, Idaho, Iowa, Kansas, Kentucky
2024-07-25
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752Relapsing Multiple Sclerosis, Multiple Sclerosis
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Recruiting
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Missouri
2024-07-18
Active, closed
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
NCT06096779Hepatocellular Carcinoma
DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab
Genentech, Inc.
Phase 2
30
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kentucky
2024-07-15
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180Advanced Melanoma
DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab
Replimune, Inc.
Phase 3
400
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Iowa
2024-07-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744Juvenile Psoriatic Arthritis
DrugsSkyrizi·Risankizumab·Adalimumab
AbbVie
Phase 3
40
Arkansas, District of Columbia, Florida, Indiana, Minnesota, New York, North Carolina, Ohio
2024-07-08
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-06-29
Active, closed
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Pfizer
Phase 1
64
Arkansas, California, Colorado, District of Columbia, Michigan, Missouri, North Carolina, Ohio
2024-06-27
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
DrugPetosemtamab
Merus B.V.
Phase 3
621
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-06-25
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-06-25
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Arizona, Colorado, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio
2024-06-25
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-06-20
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273Large B-cell Lymphoma
DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 2
250
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Georgia
2024-06-18
Active, closed
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
80
Delaware, District of Columbia, Illinois, Wisconsin
2024-06-17
Active, closed
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643Parkinson Disease
DrugAAV2-GDNF gene therapy
AskBio Inc
Phase 2
127
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-06-11
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976Hypochondroplasia
QED Therapeutics, a BridgeBio company
Observational
150
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab
Immunocore Ltd
Phase 3
680
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-06-05
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
DrugsNavtemadlin·Jakavi·Ruxolitinib
Kartos Therapeutics, Inc.
Phase 3
600
Alabama, Arizona, California, Colorado, Delaware, District of Columbia, Florida, Iowa
2024-06-03
Active, closed
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 2/3
65
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Michigan
2024-05-29
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2024-05-20
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-05-06
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDato-DXd·Osimertinib
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Recruiting
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
NCT06384807Solid Tumor
DrugCemiplimab
Biohaven Therapeutics Ltd.
Phase 1/2
500
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New York, Oklahoma
2024-04-22
Active, closed
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656Septic Shock
ExThera Medical Corporation
Not applicable
15
District of Columbia, Georgia, Michigan, Minnesota, Oregon, Pennsylvania, Texas
2024-04-19
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-04-16
Active, closed
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093Carcinoma, Non-Small-Cell Lung
DrugsTremelimumab·Durvalumab·Pemetrexed·Cisplatin
AstraZeneca
Phase 2
103
California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts
2024-04-04
Active, closed
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151Prostate Cancer, Prostate Adenocarcinoma
Curium US LLC
Phase 3
439
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Iowa
2024-04-01
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-03-21
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices
Not applicable
1,500
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-03-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Arizona, California, District of Columbia, Illinois, Louisiana, Maryland, Minnesota, New York
2024-03-14
Recruiting
Tracking Results of Ablations to Combat AF Registry Generation 2
NCT05111015Atrial Fibrillation
AtriCure, Inc.
Observational
10,000
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Indiana, Kansas
2024-03-11
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-03-05
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Active, closed
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173Alzheimer Disease
Acumen Pharmaceuticals
Phase 2
542
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Mississippi
2024-02-29
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida
2024-02-28
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,250
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-02-21
By invitation
An Observational Study of Patients With Chronic Liver Disease
NCT05744713Chronic Liver Disease, Cirrhosis
Target PharmaSolutions, Inc.
Observational
500,000
California, District of Columbia, Illinois, New York, North Carolina, Pennsylvania, Texas
2024-02-19
Active, closed
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738Small Cell Lung Carcinoma (SCLC)
DrugsObrixtamig·Topotecan
Boehringer Ingelheim
Phase 1
69
District of Columbia, Florida, Virginia
2024-02-14
Recruiting
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505Small Cell Lung Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
120
Alabama, California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland
2024-02-08
By invitation
An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
NCT06270719Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Observational
500
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-02-07
Recruiting
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals
Observational
40
California, Colorado, District of Columbia, North Carolina, Ohio, Tennessee, Texas
2024-02-06
Active, closed
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705Glenohumeral Osteoarthritis
Pacira Pharmaceuticals, Inc
Phase 3
150
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Kansas, Louisiana
2024-02-05
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
District of Columbia, Massachusetts, North Carolina, Ohio, Texas, Wisconsin
2024-02-01
Active, closed
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DrugsTucatinib·Eribulin·Herceptin·Trastuzumab
Criterium, Inc.
Phase 2
17
Colorado, District of Columbia, New Mexico, Washington, Wisconsin
2024-01-30
Active, closed
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
NCT06107426Parkinson's Disease (PD)
AbbVie
Observational
427
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Louisiana, Massachusetts
2024-01-24
Active, closed
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075Advanced Cancer
DrugDocetaxel
Arcus Biosciences, Inc.
Phase 1
91
Colorado, District of Columbia, Georgia, Michigan, New York, Pennsylvania, Texas, Utah
2024-01-19
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Montana
2024-01-18
Active, closed
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459Hemophilia B
Regeneron Pharmaceuticals
Observational
11
Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio
2024-01-17
Active, closed
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
NCT05818150Knee Osteoarthritis
Merit Medical Systems, Inc.
Not applicable
264
California, District of Columbia, Georgia, Illinois, Massachusetts, Missouri, New Jersey, New York
2024-01-16
Recruiting
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
NCT05919680Intestinal Failure Associated Liver Disease
NorthSea Therapeutics B.V.
Phase 2
36
Arizona, California, District of Columbia, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2024-01-15
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts
2024-01-11
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-01-11
Active, closed
Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children
NCT06285812Otitis Media Acute
PhotoniCare, Inc.
Observational
700
District of Columbia, Florida, New York, Oregon, South Carolina, Tennessee
2024-01-10
Active, closed
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632Advanced or Metastatic Breast Cancer
DrugsExemestane·Everolimus·Fulvestrant
Pfizer
Phase 2
333
California, District of Columbia, Montana, Texas
2024-01-09
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2023-12-27
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga
Merck Sharp & Dohme LLC
Phase 3
1,314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-18
Active, closed
Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population
NCT07382076Activated Clotting Time
Abbott Point of Care
Observational
500
Arizona, California, District of Columbia, Kentucky, Maryland, Minnesota, Missouri, New York
2023-12-15
Active, closed
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Hepatocellular Carcinoma
DrugAZD5851
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-12-14
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugNexiguran ziclumeran
Intellia Therapeutics
Phase 3
1,200
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-13
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Abemaciclib·Ribociclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kentucky, Maine
2023-12-11
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Maryland
2023-12-08
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
1,650
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-01
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-29
By invitation
Evaluation of the GORE® Ascending Stent Graft
NCT05800743Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection, Aorta; Lesion
W.L.Gore & Associates
Not applicable
370
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-11-28
Recruiting
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947Hypochondroplasia
BioMarin Pharmaceutical
Observational
400
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota
2023-11-27
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2/3
232
California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon
2023-11-24
By invitation
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
NCT06115642Advanced/Metastatic Malignant Solid Tumors
DrugsHLX43·Slulimumab·Serplulimab
Shanghai Henlius Biotech
Phase 1
367
California, District of Columbia, Texas
2023-11-24
Active, closed
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329Pre-Exposure Prophylaxis of HIV Infection
DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir
Gilead Sciences
Phase 2
253
Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina
2023-11-17
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
652
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-11-11
Recruiting
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT06230185TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Personalis Inc.
Observational
422
Arizona, Colorado, District of Columbia, Florida, Illinois, Louisiana, Michigan, Nebraska
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Active, closed
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565Hepatocellular Carcinoma
Boston Scientific Corporation
Phase 2
100
California, District of Columbia, Florida, Illinois, Louisiana, Minnesota, Missouri, New York
2023-11-03
Recruiting
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Vaxiion Therapeutics
Phase 1
48
Arizona, Colorado, District of Columbia, Massachusetts, New Hampshire, New Jersey, Ohio
2023-11-02
Recruiting
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211Single Ventricle Heart Disease
Mezzion Pharma Co. Ltd
Phase 3
436
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-30
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
DrugTreprostinil
United Therapeutics
Phase 3
698
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-10-30
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,109
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-10-25
By invitation
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
NCT06126380Kidney Transplant Rejection
DrugsTegoprubart·Tacrolimus
Eledon Pharmaceuticals
Phase 2
132
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2023-10-25
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-25
Recruiting
Nectero EAST System Clinical Study
NCT06001918Abdominal Aortic Aneurysm
Nectero Medical, Inc.
Phase 2/3
400
Arizona, Colorado, District of Columbia, Florida, Georgia, Illinois, Maine, Massachusetts
2023-10-25
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
California, Colorado, District of Columbia, Florida, Illinois, Iowa, Maryland, Massachusetts
2023-10-23
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab
Hoffmann-La Roche
Phase 3
182
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Michigan, Missouri
2023-10-22
Active, closed
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
960
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2023-10-20
Recruiting
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970Lymphatic Malformation
DrugTARA-002
Protara Therapeutics
Phase 2
38
Alabama, Arkansas, Colorado, District of Columbia, Florida, New York, Ohio, Oregon
2023-10-18
Active, closed
Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
NCT05295628Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement
Emblok, Inc.
Not applicable
532
Arizona, California, Connecticut, District of Columbia, Illinois, Iowa, Kansas, Louisiana
2023-10-17
Active, closed
J-Valve TF Early Feasibility Study
NCT06034028Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
25
Arizona, District of Columbia, Illinois, Louisiana, New York, Ohio, Texas, Washington
2023-10-16
Active, closed
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
NCT06109649Vitiligo
Clinuvel, Inc.
Phase 3
200
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Michigan
2023-10-11
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 3
14,550
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-10-09
By invitation
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
NCT06315023Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions
Endologix
Observational
450
California, Connecticut, District of Columbia, Florida, Massachusetts, Missouri, New York, Ohio
2023-10-06
Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861Acute Coronary Syndrome
DalCor Pharmaceuticals
Phase 3
2,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-10-03
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
DrugsUpadacitinib·Tocilizumab
AbbVie
Phase 3
90
Arizona, District of Columbia, New York, North Carolina, Ohio, Oregon
2023-10-02
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
NCT05987449Hemophilia A
Hoffmann-La Roche
Phase 1/2
60
California, District of Columbia, Indiana, Iowa
2023-09-21
Active, closed
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
NCT05907564Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases
Inquis Medical, Inc.
Not applicable
120
Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Louisiana
2023-09-20
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Alaska, California, Colorado, Connecticut, District of Columbia, Florida, Hawaii, Illinois
2023-09-18
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab
Hoffmann-La Roche
Phase 3
687
Arkansas, California, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2023-09-14
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Maryland, Michigan
2023-09-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Arizona, California, District of Columbia, Maryland, Massachusetts, Michigan, Nevada, New Jersey
2023-09-08
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2023-08-31
Recruiting
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities
NCT05361941Periprosthetic Joint Infections
Elute, Inc.
Not applicable
204
California, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Michigan, New York
2023-08-31
Active, closed
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-08-30
Active, closed
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT05996471HIV Infections
DrugsVH3810109·Phesgo·Cabotegravir
ViiV Healthcare
Phase 2
185
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2023-08-17
Active, closed
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
NCT05771480Biliary Tract Cancer
DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin
AstraZeneca
Phase 3
142
Alabama, California, District of Columbia, Oregon
2023-08-16
Active, closed
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522Tourette Syndrome
Emalex Biosciences Inc.
Phase 3
150
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-08-16
Recruiting
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272Uterine Fibroids, Endometriosis
DrugMyfembree
Sumitomo Pharma Switzerland GmbH
Phase 3
1,000
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-08-14
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 4
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-08-14
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
DrugIza-bren
SystImmune Inc.
Phase 1
540
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa, Kentucky
2023-08-08
Active, closed
The BD Liverty™ TIPS Stent Graft Study
NCT05711316Portal Hypertension, TIPS
C. R. Bard
Not applicable
177
California, District of Columbia, Indiana, Kansas, Massachusetts, Missouri, New Jersey, New York
2023-08-08
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-08-01
Recruiting
Pediatric Percutaneous Ultrasound Gastrostomy Technique
NCT05966311Gastrostomy, Gastrostomy Complications, Pediatric Disorder, Ultrasound
CoapTech
Not applicable
80
District of Columbia, New York, Pennsylvania
2023-07-07
Recruiting
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
NCT05674656HIV Infections
ViiV Healthcare
Phase 1/2
20
California, District of Columbia, Florida, Georgia, Texas
2023-07-06
Active, closed
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656Early Alzheimer's Disease
Cognition Therapeutics
Phase 2
540
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2023-06-28
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Arizona, California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Kansas
2023-06-27
Active, closed
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05768854Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 3
69
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois
2023-06-14
Recruiting
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963Relapsing Multiple Sclerosis
DrugUblituximab
TG Therapeutics, Inc.
Phase 3
800
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-06-13
Active, closed
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
NCT05889273Autism Spectrum Disorder
MapLight Therapeutics
Phase 2
120
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri
2023-06-01
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
DrugVericiguat
Merck Sharp & Dohme LLC
Phase 2/3
342
California, Colorado, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-05-31
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
DrugsLonsurf·MFOLFOX6·Trifluridine/Tipiracil·Avastin
Parabilis Medicines, Inc.
Phase 1/2
619
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts
2023-05-23
Recruiting
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
DrugLurbinectedin
Jazz Pharmaceuticals
Phase 1/2
60
California, District of Columbia, Florida, Georgia, Maryland, Michigan, New York, Ohio
2023-05-23
Active, closed
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
NCT05729568HIV-1 Infection
DrugsTeropavimab·Zinlirvimab·Lenacapavir
Gilead Sciences
Phase 2
83
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Missouri, New Mexico
2023-05-15
Recruiting
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
DrugsRondecabtagene autoleucel·Fludarabine·Cyclophosphamide
Lyell Immunopharma, Inc.
Phase 1/2
270
California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky, Louisiana
2023-05-09
Recruiting
Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries
NCT05496296Pressure Ulcers Stage II, Pressure Ulcers Stage III, Pressure Ulcer, Stage IV
ULURU Inc.
Not applicable
300
California, District of Columbia, Illinois, Maryland, New Jersey, New York, Pennsylvania, Texas
2023-04-30
Active, closed
Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)
NCT05870124Peripheral Neuralgia, Peripheral Neuropathy, Chronic Pain
Nalu Medical, Inc.
Not applicable
185
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, New Jersey
2023-04-27
Recruiting
Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds
NCT05743283Wound Heal
Synedgen, Inc.
Not applicable
100
District of Columbia, Missouri
2023-04-12
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-04-11
Recruiting
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
NCT05795465Respiratory Distress Syndrome, Acute
GEn1E Lifesciences
Phase 2
52
District of Columbia, Kansas, Maryland, Mississippi, Missouri, New Jersey, New York, Ohio
2023-04-04
Recruiting
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
NCT05440708Hepatocellular Carcinoma
DrugsTecentriq·Avastin·Atezolizumab·Keytruda
Tvardi Therapeutics, Incorporated
Phase 1/2
193
Alabama, California, Colorado, District of Columbia, Florida, Maryland, Michigan, Missouri
2023-03-23
Recruiting
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT05775523Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
Observational
500
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Indiana
2023-03-20
Recruiting
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
NCT05820672Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
Observational
900
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Indiana
2023-03-20
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Alabama, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Maryland
2023-03-17
Active, closed
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
NCT05766501HIV Infection
DrugDOR/ISL
Merck Sharp & Dohme LLC
Phase 3
641
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Missouri, New Jersey
2023-03-17
Active, closed
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
NCT05705349HIV-1 Infection
DrugsDOR/ISL·B/F/TAF
Merck Sharp & Dohme LLC
Phase 3
537
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2023-03-08
Recruiting
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
NCT05768919Glioblastoma
SignPath Pharma, Inc.
Phase 1/2
30
District of Columbia, Maryland
2023-03-03
Active, closed
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study
NCT05489588Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
W.L.Gore & Associates
Not applicable
165
California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan, New Jersey
2023-03-02
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-27
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
DBV Technologies
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2023-02-21
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
NCT05631093HIV-1 Infection
DrugsDOR/ISL·B/F/TAF
Merck Sharp & Dohme LLC
Phase 3
553
California, District of Columbia, Florida, Georgia, New Jersey, Pennsylvania, Texas
2023-02-20
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
NCT05630755HIV-1 Infection
DrugsDOR/ISL·B/F/TAF
Merck Sharp & Dohme LLC
Phase 3
514
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-02-17
Active, closed
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881Respiratory Syncytial Virus, Human Metapneumovirus
DrugsMRNA-1345·MRNA-1365·Nimenrix
ModernaTX, Inc.
Phase 1
186
California, District of Columbia, Illinois, Louisiana, North Carolina, Rhode Island, South Carolina, Tennessee
2023-02-15
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-15
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Iowa
2023-02-03
Active, closed
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
NCT05723835SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugSomapacitan
Novo Nordisk A/S
Phase 3
47
Alabama, California, Colorado, District of Columbia, Idaho, Minnesota
2023-02-01
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-01-25
Active, closed
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220Breast Cancer, Metastatic Breast Cancer
DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus
Stemline Therapeutics, Inc.
Phase 1/2
435
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-01-24
Recruiting
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258Autosomal Recessive Polycystic Kidney (ARPKD)
DrugTolvaptan
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
20
District of Columbia, Georgia, Illinois, Indiana, Louisiana, Maryland, Michigan, Minnesota
2023-01-23
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
DrugDordaviprone
Jazz Pharmaceuticals
Phase 3
510
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2023-01-23
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
42
California, Colorado, District of Columbia, Ohio, Pennsylvania, Tennessee, Washington, Wisconsin
2023-01-19
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-01-06
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-01-05
Active, closed
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT05630209Brain Tumor
DrugsAdriamycin·Doxorubicin
InSightec
Phase 1/2
10
District of Columbia, Florida, Texas
2023-01-04
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2022-12-21
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916Breast Cancer
Greenwich LifeSciences, Inc.
Phase 3
2,250
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-16
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
7,297
Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida
2022-12-14
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2022-12-13
Active, closed
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
NCT05364502Arterial Bleeding in Solid Organs and Peripheral Arteries
Instylla, Inc.
Not applicable
130
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Maryland
2022-12-12
Active, closed
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316Advanced Melanoma
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 2
150
Arizona, California, Connecticut, District of Columbia, Massachusetts, New Jersey
2022-12-12
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine
Gilead Sciences
Phase 3
1,514
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-12
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin
AbbVie
Phase 1
288
Arizona, California, Connecticut, District of Columbia, Illinois, Indiana, Iowa, Michigan
2022-12-05
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
DrugCamlipixant
Bellus Health Inc. - a GSK company
Phase 3
997
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2022-12-05
By invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2022-11-30
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
DrugsDato-DXd·Xeloda·Durvalumab·Keytruda
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2022-11-21
Active, closed
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
NCT05295290Myocarditis
Pfizer
Phase 4
319
California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Louisiana, Massachusetts
2022-11-21
By invitation
EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
NCT05610787Heart Failure, Transplant; Failure, Heart, Congenital Heart Disease
Berlin Heart, Inc
Not applicable
40
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Missouri
2022-11-14
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin
Janssen Research & Development, LLC
Phase 2
520
California, District of Columbia, Florida, Kansas, Maryland, Massachusetts, Missouri, New Jersey
2022-11-11
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283Chronic Kidney Disease, Proteinuria, Children
DrugFinerenone
Bayer
Phase 3
100
Arizona, California, District of Columbia, Florida, Georgia, Iowa, Maryland, Massachusetts
2022-11-08
Recruiting
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
NCT05452941Pneumonia
Pfizer
Observational
12,500
California, Connecticut, District of Columbia, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-27
Active, closed
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
NCT05409976Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
W.L.Gore & Associates
Not applicable
136
California, District of Columbia, Illinois, Michigan, New York, North Carolina, Virginia
2022-10-25
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Arizona, Arkansas, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2022-10-13
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
California, District of Columbia, Florida, Illinois, North Carolina, Ohio, Oregon, Pennsylvania
2022-10-12
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-10-04
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NCT05443126NSCLC
DrugPemetrexed
Ellipses Pharma
Phase 1/2
265
California, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan, New York
2022-09-30
Active, closed
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
NCT05482971Essential Thrombocythemia
DrugBesremi
PharmaEssentia
Phase 2
91
Alabama, California, Connecticut, District of Columbia, Georgia, Indiana, Kentucky, Louisiana
2022-09-29
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
DrugSatralizumab
Hoffmann-La Roche
Phase 3
122
Alabama, California, Colorado, District of Columbia, Georgia, Maryland, Massachusetts, Minnesota
2022-09-27
Rows per page Showing 1–500 of 802
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/district-of-columbia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 802 of those studies with a site in District of Columbia.

How many clinical trials are recruiting in District of Columbia?

386 of the 802 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 11 have not yet opened recruitment, 377 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (District of Columbia), 802 studies
PhaseStudiesRecruitingShare
Phase 334416542.9%
Phase 21185314.7%
Not applicable1023412.7%
Observational874710.8%
Phase 1/263407.9%
Phase 140205%
Phase 2/338224.7%
Phase 41051.2%

Most active sponsors

Lead sponsors with the most studies (District of Columbia)
Lead sponsorStudiesRecruiting
AstraZeneca4521
Merck Sharp & Dohme LLC4419
Pfizer2515
Novartis Pharmaceuticals2413
Hoffmann-La Roche227
Gilead Sciences162
Bristol-Myers Squibb149
Janssen Research & Development, LLC146
Eli Lilly and Company128
Sanofi126
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.